Torrent Pharmaceuticals Ltd.'s bottom line surged 20% during the quarter ended June 30, 2025, for the fiscal 2026.
The Ahmedabad-based drug maker's profit soared to Rs 548 crore for the April-June period, against Rs 457 crore for the same period last year, according to an exchange filing on Monday.
Torrent Pharma Q1 Highlights (Consolidated, YoY)
Revenue up 11.2% to Rs 3,178 crore versus Rs 2,859 crore.
Net profit up 20% to Rs 548 crore versus Rs 457 crore.
Ebitda up 14% to Rs 1,032 crore versus Rs 904 crore.
Margin at 32.5% versus 31.6%.
The revenue from Torrent Pharma's Germany business climbed 9% to Rs 308 crore for the first quarter. Its Brazil portfolio recorded a rise in its top line to Rs 218 crore during the April-June period, denoting a 11% surge.
The company's US business revenue soared by 19% to Rs 308 crore.
Shares of Torrent Pharma closed 0.53% higher at Rs 3,622.9 apiece on the NSE, compared to a 0.63% fall in the benchmark Nifty. The stock has risen 13.27% in the last 12 months and 7.82% on a year-to-date basis.
Out of 32 analysts tracking the company, 19 have a 'buy' rating on the stock, 10 recommend 'hold' and three gave 'sell', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 1.5%.
RECOMMENDED FOR YOU
Torrent Pharma Q1 Review: Citi Hikes Target Price — Here's Why
Jul 29, 2025
Cipla Q1 Results: Net Profit Rises 10% To Rs 1,298 Crore, Beats Estimates
Jul 25, 2025
Westlife Foodworld Q1 Results: Revenue Up Over 6% But Profit Declines
Jul 23, 2025
Mid-Cap Stocks To Buy, Sell Or Hold: Torrent Pharma, One97 Communications—Check Target Price
Jul 16, 2025
POPULAR